• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗逆转录病毒耐药性对病毒适应性的影响。

Implications of antiretroviral resistance on viral fitness.

作者信息

Nijhuis M, Deeks S, Boucher C

机构信息

Eijkman-Winkler Institute, Department of Virology, University Medical Center, Heidelberglaan, Utrecht, The Netherlands.

出版信息

Curr Opin Infect Dis. 2001 Feb;14(1):23-8. doi: 10.1097/00001432-200102000-00005.

DOI:10.1097/00001432-200102000-00005
PMID:11979111
Abstract

Treatment of HIV infected patients with antiretroviral drugs often results in the emergence of virus variants with reduced sensitivity to these drugs. However, the viral load often remains partially suppressed below pretherapy levels, which might be explained by a reduced fitness of the drug resistant viral population. This review describes the effects of antiretroviral resistance development on the fitness of the viral population and its clinical implications.

摘要

用抗逆转录病毒药物治疗HIV感染患者常常会导致出现对这些药物敏感性降低的病毒变体。然而,病毒载量往往仍会部分抑制在治疗前水平以下,这可能是由于耐药病毒群体适应性降低所致。本综述描述了抗逆转录病毒耐药性的产生对病毒群体适应性的影响及其临床意义。

相似文献

1
Implications of antiretroviral resistance on viral fitness.抗逆转录病毒耐药性对病毒适应性的影响。
Curr Opin Infect Dis. 2001 Feb;14(1):23-8. doi: 10.1097/00001432-200102000-00005.
2
Antiretroviral resistance.抗逆转录病毒耐药性
J HIV Ther. 2006 Dec;11(4):72-3.
3
The clinical significance of viral fitness.病毒适应性的临床意义。
J HIV Ther. 2005 Mar;10(1):6-10.
4
In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.在接受高效抗逆转录病毒治疗的1型人类免疫缺陷病毒感染患者的纵向血浆样本中,病毒载量低于50拷贝/mL时体内出现耐药性突变,这些突变在病毒反弹时仍持续存在。
J Hum Virol. 2001 Nov-Dec;4(6):317-28.
5
Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.一线治疗失败后,感染人类免疫缺陷病毒-1 的莫桑比克儿童出现病毒耐药性延长的风险。
Pediatr Infect Dis J. 2009 Dec;28(12):e283-7. doi: 10.1097/INF.0b013e3181ba6c92.
6
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.人类免疫缺陷病毒基因耐药性检测对治疗效果的影响研究。
Verh K Acad Geneeskd Belg. 2001;63(5):447-73.
7
Predicting antiretroviral drug resistance from the latest or the cumulative genotype.根据最新或累积基因型预测抗逆转录病毒药物耐药性。
Antivir Ther. 2011;16(3):373-82. doi: 10.3851/IMP1753.
8
Antiretroviral Resistance Mutations (revised April 2001).抗逆转录病毒耐药性突变(2001年4月修订)
HIV Clin Trials. 2001 Jul-Aug;2(4):346-55. doi: 10.1310/8FXB-B0EK-D525-BVU3.
9
HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.HIV-1逆转录酶抑制剂耐药性突变与适应性:临床及体外研究视角
Virus Res. 2008 Jun;134(1-2):104-23. doi: 10.1016/j.virusres.2007.12.021. Epub 2008 Mar 4.
10
Genotypic resistance tests for the clinical management of patients with primary HIV infection.用于初发HIV感染患者临床管理的基因型耐药检测
Scand J Infect Dis Suppl. 2003;106:66-70.

引用本文的文献

1
Over time analysis of the codon usage of SARS-CoV-2 and its variants.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)及其变体密码子使用情况的长期分析。
Comput Struct Biotechnol J. 2025 May 20;27:2034-2050. doi: 10.1016/j.csbj.2025.05.021. eCollection 2025.
2
Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation.神经症状性 HIV-1 脑脊液逃逸与中枢神经系统 T 细胞复制和炎症有关。
J Clin Invest. 2024 Oct 1;134(19):e176358. doi: 10.1172/JCI176358.
3
Evolution Driven By A Varying Host Environment Selects For Distinct HIV-1 Entry Phenotypes and Other Informative Variants.
由不断变化的宿主环境驱动的进化选择了不同的HIV-1进入表型和其他信息性变体。
Front Virol. 2023;3. doi: 10.3389/fviro.2023.1291996. Epub 2023 Nov 16.
4
Intragenic compensation through the lens of deep mutational scanning.从深度突变扫描视角看基因内补偿
Biophys Rev. 2022 Oct 26;14(5):1161-1182. doi: 10.1007/s12551-022-01005-w. eCollection 2022 Oct.
5
Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.SARS-CoV-2 主蛋白酶(Mpro)对蛋白酶抑制剂的潜在耐药性:从 HIV-1 蛋白酶中吸取的教训。
Int J Mol Sci. 2022 Mar 23;23(7):3507. doi: 10.3390/ijms23073507.
6
Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.抗 HIV 治疗药物的发现与开发:迈向改善 HIV 药物治疗的进展。
Curr Top Med Chem. 2019;19(18):1621-1649. doi: 10.2174/1568026619666190712204603.
7
A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors.一种用于评估HIV-1对蛋白酶抑制剂耐药性的无细胞酶活性测定法。
Front Microbiol. 2015 Oct 31;6:1220. doi: 10.3389/fmicb.2015.01220. eCollection 2015.
8
Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.逆转录酶中第65和66密码子的沉默突变减轻了插入缺失的形成,并恢复了含有D67N和K70R耐药突变的B型HIV-1的适应性。
Nucleic Acids Res. 2015 Mar 31;43(6):3256-71. doi: 10.1093/nar/gkv128. Epub 2015 Mar 12.
9
Current progress in antiviral strategies.抗病毒策略的当前进展。
Trends Pharmacol Sci. 2014 Feb;35(2):86-102. doi: 10.1016/j.tips.2013.11.006. Epub 2014 Jan 14.
10
Community HIV-1 drug resistance is associated with transmitted drug resistance.社区获得性HIV-1耐药性与传播性耐药性相关。
HIV Med. 2014 Jul;15(6):339-46. doi: 10.1111/hiv.12122. Epub 2014 Jan 12.